Neuropathix (TYGS) Return on Equity ROE from the first quarter 2022 to first quarter 2021 and annually, average high and low, overall ranking from Mar 31 2022 to Mar 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neuropathix Inc.  (TYGS)

Neuropathix's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Neuropathix in the first quarter 2022?
Due to the lack of equity, it was not possible to calculate Neuropathix Inc.'s return on equity (ROE) in its first quarter 2022

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -4 -4 -4 -4 -6
Return On Equity (TTM) - - - - -
TYGS's Total Ranking # # # # #
Equity (TTM) in Millions -5 -4 -4 -3 -3
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to TYGS Management Effectiveness >> TYGS's 5 Years Annual ROE >> Compare TYGS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





TYGS Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Equity in Millions -4 -3 -2 1 0
Y / Y Equity Change - - - - -
Net Income in Millions -4 -5 -3 1 0
Y / Y Net Income Change - - - - -
Return On Equity - - - 69.96 % -

Back to TYGS Management Effectiveness >> TYGS's 5 Years Annual ROE >> Compare TYGS ROE to its Competitors




Annual Roe Comment
In 2021 ROE improved to 69.96 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TYGS's' Return on Equity at Yahoo Finance
TYGS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TYGS's Competitors
Subscribers only: Roe for Neuropathix's Suppliers
Subscribers only: Return On Equity for TYGS's Customers




Companies with similar Return On Equity at Mar 31 2022, within Healthcare Sector ROE
Lianbio  230.93 %
Biovie Inc   222.13 %
Waters Corporation  215.79 %
Halozyme Therapeutics Inc   202.61 %
Cartesian Therapeutics Inc   200.16 %
Warby Parker Inc   193.86 %
Procept Biorobotics Corporation  170.48 %
Avid Bioservices Inc   156.25 %
Entrada Therapeutics Inc   143.64 %
Moderna Inc   121.86 %
Molecular Templates Inc   110.16 %
Idexx Laboratories Inc  103.69 %
REST EZ Inc.  99.51 %
Vyne Therapeutics Inc   96.49 %
Vir Biotechnology Inc   96.39 %
Ironwood Pharmaceuticals inc   95.21 %
Amgen Inc   95.07 %
Davita Inc   94.90 %
Maravai Lifesciences Holdings Inc   92.72 %
Vicarious Surgical Inc  91.60 %
Journey Medical Corp  89.42 %
Tenet Healthcare Corp  88.75 %
Abbvie Inc   86.23 %
Tivity Health Inc   81.80 %
Sensus Healthcare Inc   77.94 %
Biomx Inc  75.95 %
Eli Lilly And Company  73.77 %
Glucotrack Inc   73.46 %
Dynavax Technologies Corporation  65.79 %
Iteos Therapeutics Inc   64.68 %

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.